Oventus Medical Ltd (ASX:OVN) is pleased to provide a copy of its latest newsletter for investors.
Oventus Medical Ltd
Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a unique treatment platform for the treatment of sleep apnoea and snoring. Unlike other oral appliances or CPAP interfaces, the Oventus devices have a unique and patented airway within the treatment platform that allows air to flow to the back of the mouth unobstructed while maintaining an oral seal and stable jaw position, bypassing multiple obstructions from the nose, soft palate and tongue, reducing airway collapsibility and managing mouth breathing while maintaining a stable airway. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, this technology actually manages mouth breathing by converting it to device breathing and normalising ventilation. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.
Oventus Medical Ltd (ASX:OVN) Innovators in Sleep Apnoea Treatment Presentation for Thorney Investment Forum
Oventus Medical Ltd (ASX:OVN) is pleased to attach a copy of the presentation that Founder and Clinical Director, Dr Chris Hart will deliver to investors this morning at the Thorney Sydney Investment Forum.
Oventus Medical Ltd (ASX:OVN) is pleased to announce positive interim data being presented today in a lecture at Macquarie University on a group of hard-to-treat obstructive sleep apnoea patients, who were studied in a sub-group as part of the ongoing "NeuRA Sydney study".
Oventus Medical Ltd (ASX:OVN) is pleased to announce the results of the OVEN-003 clinical trial study being conducted in Brisbane by the company, a randomised controlled clinical trial examining the treatment outcomes of oral appliance therapy with and without 'Oventus Airway Technology'.
Oventus Medical Ltd (ASX:OVN) announces its Appendix 4C Report for the three-month period ending 31 March 2018 (Q3 FY2018) and is pleased to provide a review of progress made during the quarter.
Oventus Medical Ltd (ASX:OVN) provide the latest Investor Presentation.
Australian medical device company, Oventus Medical Ltd. (ASX:OVN) is pleased to release its Appendix 4E with its full year audited general purpose financial report for the period ending 30 June 2017.
Australian medical device company, Oventus Medical Ltd. (ASX:OVN) is pleased to share Dr Chris Hart's interview on Financial News Network.
Australian medical device company, Oventus Medical Ltd. (ASX:OVN) has today released its Appendix 4C - Quarterly cash flow report for the period ended 30 June 2017.
Oventus Medical Limited (ASX:OVN) announced a share purchase plan to the market on 22 June 2017. Oventus wishes to advise that the closing date for the SPP will be extended from Wednesday 19 July 2017 to Monday 31 July 2017.